An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers

Cancer Cell

Volumn 30, Issue 5, 2016, Pages 683-693

  Villa, Genaro R ^a,b   Hulce, Jonathan J ^c   Zanca, Ciro ^b   Bi, Junfeng ^b   Ikegami, Shiro ^b   Cahill, Gabrielle L ^b   Gu, Yuchao ^a,b   Lum, Kenneth M ^c   Masui, Kenta ^d   Yang, Huijun ^b   Rong, Xin ^a   Hong, Cynthia ^a   Turner, Kristen M ^b   Liu, Feng ^b   Hon, Gary C ^b   Jenkins, David ^b   Martini, Michael ^c   Armando, Aaron M ^e   Quehenberger, Oswald ^e   Cloughesy, Timothy F ^a   Furnari, Frank B ^b,e,f   Cavenee, Webster K ^b,e,f   Tontonoz, Peter ^a,g   Gahman, Timothy C ^b   Shiau, Andrew K ^b   Cravatt, Benjamin F ^c   Mischel, Paul S ^b,e,f   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

brain cancer; cholesterol; glioblastoma; liver X receptor; metabolism; oxysterols

Indexed keywords

CHOLESTEROL; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; MEVINOLIN; UNCLASSIFIED DRUG; [2 (2 CHLORO 4 FLUOROBENZYL) 3 (4 FLUOROPHENYL) 7 (TRIFLUOROMETHYL) 2H INDAZOLE]; 2-(2-CHLORO-4-FLUOROBENZYL)-3-(4-FLUOROPHENYL)-7-(TRIFLUOROMETHYL)-2H-INDAZOLE; INDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CANCER; CANCER REGRESSION; CANCER SURVIVAL; CELL DEATH; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BRAIN NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GLIOBLASTOMA; HUMAN; METABOLISM; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL; FEMALE; GLIOBLASTOMA; HUMANS; INDAZOLES; LIVER X RECEPTORS; MICE; TREATMENT OUTCOME;

EID: 85006435245     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.09.008     Document Type: Article

References (55)

1. Björkhem, I., Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J. Intern. Med. 260 (2006), 493–508.
2. Björkhem, I., Meaney, S., Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 806–815.
3. Bovenga, F., Sabbà, C., Moschetta, A., Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 21 (2015), 517–526.
4. Bradley, M.N., Hong, C., Chen, M., Joseph, S.B., Wilpitz, D.C., Wang, X., Lusis, A.J., Collins, A., Hseuh, W.A., Collins, J.L., et al. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J. Clin. Invest. 117 (2007), 2337–2346.
5. Brastianos, P.K., Carter, S.L., Santagata, S., Cahill, D.P., Taylor-Weiner, A., Jones, R.T., Van Allen, E.M., Lawrence, M.S., Horowitz, P.M., Cibulskis, K., et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5 (2015), 1164–1177.
6. Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al. The somatic genomic landscape of glioblastoma. Cell 155 (2013), 462–477.
7. Brown, M.S., Goldstein, J.L., Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21 (1980), 505–517.
8. Caliceti, C., Zambonin, L., Prata, C., Vieceli Dalla Sega, F., Hakim, G., Hrelia, S., Fiorentini, D., Effect of plasma membrane cholesterol depletion on glucose transport regulation in leukemia cells. PLoS One, 7, 2012, e41246.
9. Cancer Genome Atlas Research Network, Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008), 1061–1068.
10. Chen, J., Zhang, X., Kusumo, H., Costa, L.G., Guizzetti, M., Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis. Biochim. Biophys. Acta 1831 (2013), 263–275.
11. Chisholm, J.W., Hong, J., Mills, S.A., Lawn, R.M., The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J. Lipid Res. 44 (2003), 2039–2048.
12. Christian, A.E., Haynes, M.P., Phillips, M.C., Rothblat, G.H., Use of cyclodextrins for manipulating cellular cholesterol content. J. Lipid Res. 38 (1997), 2264–2272.
13. Cloughesy, T.F., Cavenee, W.K., Mischel, P.S., Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. Mech. Dis. 9 (2014), 1–25.
14. Deeken, J.F., Löscher, W., The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13 (2007), 1663–1674.
15. Dietschy, J.M., Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 390 (2009), 287–293.
16. Dietschy, J.M., Turley, S.D., Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12 (2001), 105–112.
17. Flaveny, C.A., Griffett, K., El-Gendy, B.E.-D.M., Kazantzis, M., Sengupta, M., Amelio, A.L., Chatterjee, A., Walker, J., Solt, L.A., Kamenecka, T.M., et al. Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. Cancer Cell 28 (2015), 42–56.
18. Furnari, F.B., Cloughesy, T.F., Cavenee, W.K., Mischel, P.S., Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 15 (2015), 302–310.
19. Gabitova, L., Restifo, D., Gorin, A., Manocha, K., Handorf, E., Yang, D.-H., Cai, K.Q., Klein-Szanto, A.J., Cunningham, D., Kratz, L.E., et al. Endogenous sterol metabolites regulate growth of EGFR/KRAS-dependent tumors via LXR. Cell Rep. 12 (2015), 1927–1938.
20. Galluzzi, L., Kepp, O., Heiden, M.G.V., Kroemer, G., Metabolic targets for cancer therapy. Nat. Rev. Drug Discov., 12, 2013, 963.
21. Gronemeyer, H., Gustafsson, J.-A., Laudet, V., Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3 (2004), 950–964.
22. Guo, D., Prins, R.M., Dang, J., Kuga, D., Iwanami, A., Soto, H., Lin, K.Y., Huang, T.T., Akhavan, D., Hock, M.B., et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal., 2, 2009, ra82.
23. Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A.N., Soto, H., Zhu, S., et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 1 (2011), 442–456.
24. Hayashi, H., Campenot, R.B., Vance, D.E., Vance, J.E., Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J. Biol. Chem. 279 (2004), 14009–14015.
25. Hong, C., Tontonoz, P., Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 13 (2014), 433–444.
26. Hulce, J.J., Cognetta, A.B., Niphakis, M.J., Tully, S.E., Cravatt, B.F., Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Nat. Methods 10 (2013), 259–264.
27. Joseph, S.B., Laffitte, B.A., Patel, P.H., Watson, M.A., Matsukuma, K.E., Walczak, R., Collins, J.L., Osborne, T.F., Tontonoz, P., Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277 (2002), 11019–11025.
28. Joseph, S.B., McKilligin, E., Pei, L., Watson, M.A., Collins, A.R., Laffitte, B.A., Chen, M., Noh, G., Goodman, J., Hagger, G.N., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99 (2002), 7604–7609.
29. Karten, B., Campenot, R.B., Vance, D.E., Vance, J.E., Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J. Biol. Chem. 281 (2006), 4049–4057.
30. Katz, A., Udata, C., Ott, E., Hickey, L., Burczynski, M.E., Burghart, P., Vesterqvist, O., Meng, X., Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol. 49 (2009), 643–649.
31. Lawrence, M.S., Stojanov, P., Mermel, C.H., Robinson, J.T., Garraway, L.A., Golub, T.R., Meyerson, M., Gabriel, S.B., Lander, E.S., Getz, G., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505 (2014), 495–501.
32. Lin, C.-Y., Gustafsson, J.-Å., Targeting liver X receptors in cancer therapeutics. Nat. Rev. Cancer 15 (2015), 216–224.
33. Lo Sasso, G., Bovenga, F., Murzilli, S., Salvatore, L., Di Tullio, G., Martelli, N., D'Orazio, A., Rainaldi, S., Vacca, M., Mangia, A., et al. Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology 144 (2013), 1497–1507 1507.e1–e13.
34. Lunt, S.Y., Vander Heiden, M.G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27 (2011), 441–464.
35. Luo, J., Solimini, N.L., Elledge, S.J., Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136 (2009), 823–837.
36. Nguyen-Vu, T., Vedin, L.-L., Liu, K., Jonsson, P., Lin, J.Z., Candelaria, N.R., Candelaria, L.P., Addanki, S., Williams, C., Gustafsson, J.-Å., et al. Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism. Breast Cancer Res., 15, 2013, R51.
37. Nieweg, K., Schaller, H., Pfrieger, F.W., Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J. Neurochem. 109 (2009), 125–134.
38. Ozawa, T., James, C.D., Establishing intracranial brain tumor xenografts with subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. J. Vis. Exp., 41, 2010, 1986.
39. Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.-H., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008), 1807–1812.
40. Pavlova, N.N., Thompson, C.B., The emerging hallmarks of cancer metabolism. Cell Metab. 23 (2016), 27–47.
41. Pencheva, N., Buss, C.G., Posada, J., Merghoub, T., Tavazoie, S.F., Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 156 (2014), 986–1001.
42. Pommier, A.J.C., Dufour, J., Alves, G., Viennois, E., De Boussac, H., Trousson, A., Volle, D.H., Caira, F., Val, P., Arnaud, P., et al. Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice. PLoS Genet., 9, 2013, e1003483.
43. Quinet, E.M., Basso, M.D., Halpern, A.R., Yates, D.W., Steffan, R.J., Clerin, V., Resmini, C., Keith, J.C., Berrodin, T.J., Feingold, I., et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J. Lipid Res. 50 (2009), 2358–2370.
44. Raj, L., Ide, T., Gurkar, A.U., Foley, M., Schenone, M., Li, X., Tolliday, N.J., Golub, T.R., Carr, S.A., Shamji, A.F., et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475 (2011), 231–234.
45. Repa, J.J., Turley, S.D., Lobaccaro, J.A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R.A., Dietschy, J.M., Mangelsdorf, D.J., Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 (2000), 1524–1529.
46. Sarkaria, J.N., Yang, L., Grogan, P.T., Kitange, G.J., Carlson, B.L., Schroeder, M.A., Galanis, E., Giannini, C., Wu, W., Dinca, E.B., et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 6 (2007), 1167–1174.
47. Schultz, J.R., Tu, H., Luk, A., Repa, J.J., Medina, J.C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D.J., et al. Role of LXRs in control of lipogenesis. Genes Dev. 14 (2000), 2831–2838.
48. Solimini, N.L., Luo, J., Elledge, S.J., Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130 (2007), 986–988.
49. Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
50. Venkateswaran, A., Laffitte, B.A., Joseph, S.B., Mak, P.A., Wilpitz, D.C., Edwards, P.A., Tontonoz, P., Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA 97 (2000), 12097–12102.
51. Vivanco, I., Robins, H.I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P.L., Kubek, S., Oldrini, B., Chheda, M.G., Yannuzzi, N., et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2 (2012), 458–471.
52. Wahrle, S.E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J.D., Kowalewski, T., Holtzman, D.M., ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279 (2004), 40987–40993.
53. Wang, M.Y., Lu, K.V., Zhu, S., Dia, E.Q., Vivanco, I., Shackleford, G.M., Cavenee, W.K., Mellinghoff, I.K., Cloughesy, T.F., Sawyers, C.L., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66 (2006), 7864–7869.
54. Wrobel, J., Steffan, R., Bowen, S.M., Magolda, R., Matelan, E., Unwalla, R., Basso, M., Clerin, V., Gardell, S.J., Nambi, P., et al. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J. Med. Chem. 51 (2008), 7161–7168.
55. Zelcer, N., Hong, C., Boyadjian, R., Tontonoz, P., LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325 (2009), 100–104.